On Oct 6-8 we will be attending both CPHI in Milan and CRN Annual Signature Event in Carlsbad, California. Hope to meet you there!
Probi, part of Symrise Group’s Care & Wellness Division, offers more than 35 years of pioneering research and global innovation capabilities to the probiotics and biotics market.
What began as groundbreaking microbiome research at Lund University in Sweden has evolved into one of the industry's most science-driven biotics companies, trusted by nutraceutical and supplement brands and consumers worldwide for clinically studied probiotic strains, science-backed ingredients, and evidence-based innovation.
Probi's story began in the mid-1980s at Lund University in Sweden, where pioneering researchers sought to understand whether specific probiotic bacteria could improve outcomes for critically ill patients and support recovery.
This work led to the discovery of Lactiplantibacillus plantarum 299v (LP299V®), the world's most clinically documented L. plantarum strain and the founding of Probi in 1991.
Over the following 35 years, Probi has expanded from this single research breakthrough into a globally recognized leader in biotics innovation, supporting supplement and F&B brands across key health areas such as immunity, women’s health, gut health and cognitive health, backed by one of the industry's most extensive collections of clinical research and scientific documentation.
From digestive and immune health to metabolic, cognitive, oral and women's health, Probi's growth has always been driven by scientific discovery, understanding the science behind probiotics and a commitment to translating research into meaningful health solutions.
Every chapter in Probi's history has been driven by science. From pioneering discoveries to strategic collaborations, these milestones have helped tailor both the company and the wider biotics category.
2025 – Today | A new chapter with Symrise
Becoming part of the Symrise Group marks a significant milestone in Probi's journey, creating new opportunities to accelerate research, expand innovation, and bring clinically documented biotic solutions to customers and consumers worldwide. The year also marked the launch of Rham27h postbiotic solution derived from Lacticaseibacillus rhamnosus 271 and provides targeted gut and immune health benefits.
2021 – 2024 | Advancing the biotics category
Strategic partnerships with BLIS Technologies and Clasado Biosciences expand expertise into oral health and synbiotics, while research progresses in metabolic health, cognitive wellbeing, and next-generation biotic solutions.
2005 – 2018 | Expanding clinical applications
Continued investment in research supports innovation across digestive health, immune health, iron absorption and bone health, broadening Probi's scientific portfolio.
1994 | Bringing science to consumers
The launch of ProViva® demonstrates the commercial potential of clinically documented probiotics and introduces LP299V® to consumers.
1991 | Probi is founded
Established to translate pioneering probiotic research into evidence-based health solutions.
1980s | The discovery of LP299V®
Research at Lund University led to the discovery of LP299V®, laying out the scientific foundation for Probi and decades of future innovation.
As part of Symrise, Probi is uniquely positioned to build on 35 years of scientific leadership to transform the future of biotics.
Probi's expertise in biotics, especially probiotics and microbiome science is complemented by Symrise's global reach, innovation capabilities and leadership in health and wellness.
This combination creates new opportunities to accelerate research, develop a next generation of clinically studied biotic strains, and support customers in addressing evolving consumer health needs.
While much has changed since Probi's founding in 1991, one thing remains constant: a commitment to improving lives through the science of biotics.
